Updated clinical recommendations, including lifestyle changes, prevention strategies and treatment options, to reduce the risk of a first stroke have been outlined in a new guideline.
AstraZeneca Plc is licensing a drug from China’s CSPC Pharmaceutical Group Ltd that it hopes will treat high cholesterol, as the pharma company seeks to bolster its cardiovascular pipeline.
(Bloomberg) -- AstraZeneca Plc is licensing a drug from China’s CSPC Pharmaceutical Group Ltd that it hopes will treat high cholesterol, as the pharma company seeks to bolster its cardiovascular ...